<DOC>
	<DOCNO>NCT00363727</DOCNO>
	<brief_summary>This study evaluate effective new formulation market drug increase time onset dyskinesia ( abnormal twisting , writhe movement ) patient Parkinson 's Disease take levodopa le 2 year .</brief_summary>
	<brief_title>Onset Motor Complications Using REQUIP CR ( Ropinirole Controlled-release ) As Add-on Therapy To L-dopa In Parkinson 's</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>Must 600mg less levodopa therapy two year less . Must stable dose levodopa therapy least 4 week prior screen . Current past history Dyskinesia . State dementia MMSE score &lt; 26 screening .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>dyskinesia</keyword>
	<keyword>SINEMET</keyword>
	<keyword>Parkinson 's disease</keyword>
	<keyword>control release ropinirole</keyword>
</DOC>